Drug
Bmab 1200
Bmab 1200: highest development phase Phase 1, developed by Biocon. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Biocon
Trials
| Drug | Phase | Indication |
|---|---|---|
| Bmab 1200 (Biosimilar Ustekinumab) NCT06738277 | Phase 1 | Moderate to Severe Chronic Plaque Psoriasis |
Latest
No recent events.
Follow Bmab 1200 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.